ImmuneOncia targets niche market in cancer immunotherapy
By | translator Alice Kang
22.12.06 06:18:45
가나다라
0
Patients with rare lymphoma that has a survival of only 6 months upon recurrence received treatment for over 1 year with IMC-001
6 out of 10 patients showed a response, and all those showed response had complete response...” will work for its rapid commercialization”
More common in Asia than in the West...a niche market where existing immuno-oncology drugs have not yet entered
“NK/T-cell lymphoma is a niche market that has no approved immunotherapy. After completing the trial in Q2 next year, we plan to promptly receive approval and extend our indication if we see good results.“
▲Heung Tae Kim, CEO of ImmuneOncia Therapeutics Inc
On the 3rd (local time), Heung Tae Kim, CEO of ImmuneOncia Therapeutics, expressed his aspirations at the ‘ESMO Asia Congress 2022’ that was held in Singapore.ImmuneOncia is a new cancer immunotherapy drug-developing company that was established as a joint venture company between Yuhan Corp and the US bio-company Sorrento. The company owns various pipelines including the PD-L1 antibody IMC-001 and the CD47 antibody IMC-002, etc.
The results that were presented were
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)